Ovarian cancer historical perspective

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer historical perspective

CDC on Ovarian cancer historical perspective

Ovarian cancer historical perspective in the news

Blogs on Ovarian cancer historical perspective

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

Ovarian cancer was first linked to gene mutations by Dr. King who found and named BRCA1 gene on chromosome 17 in 1990 and BRCA2 gene on chromosome 13 in 1994.

Historical Perspective

References

  1. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L; et al. (2009). "Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology". J Clin Oncol. 27 (5): 812–26. doi:10.1200/JCO.2008.21.2134. PMC 2645086. PMID 19103723.
  2. Diamandopoulos GT (1996). "Cancer: an historical perspective". Anticancer Res. 16 (4A): 1595–602. PMID 8712676.
  3. Hajdu SI (2011). "A note from history: landmarks in history of cancer, part 1". Cancer. 117 (5): 1097–102. doi:10.1002/cncr.25553. PMID 20960499.
  4. Apostolou, Paraskevi; Fostira, Florentia (2013). "Hereditary Breast Cancer: The Era of New Susceptibility Genes". BioMed Research International. 2013: 1–11. doi:10.1155/2013/747318. ISSN 2314-6133.
  5. Godet, Inês; M. Gilkes, Daniele (2017). "BRCA1 and BRCA2 mutations and treatment strategies for breast cancer". Integrative Cancer Science and Therapeutics. 4 (1). doi:10.15761/ICST.1000228. ISSN 2056-4546.

Template:WH

Template:WS